1stOncology™: Cancer Intelligence Service – Page 11672 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting

On June 17, 2020 Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence ("A.I."), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, reported that it will make two presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2020 Virtual Annual Meeting, a meeting of global leaders in cancer research taking place from June 22-24, 2020 (Press release, Lantern Pharma, JUN 17, 2020, View Source;utm_medium=rss&utm_campaign=lantern-pharma-announces-two-presentations-at-american-association-for-cancer-research-aacr-2020-virtual-annual-meeting [SID1234561216]). They represent the Company’s first two presentations since its IPO and subsequent listing on Nasdaq under the ticker symbol ‘LTRN.’

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Each presentation will examine Lantern Pharma’s use of its A.I. platform, RADR (Response Algorithm for Drug Positioning and Rescue), in the development of LP-184, one of three cancer drugs in Lantern Pharma’s pipeline. The first abstract will focus on LP-184’s unique features, including its nanomolar potency and its activity in multi-drug resistant tumors, while the second abstract will highlight Lantern Pharma’s use of machine learning, specifically artificial neural networks, to pinpoint a genomic signature most closely correlated with predicting response to LP-184 across a range of solid tumors and central nervous system (CNS) cancers. This signature is aimed at facilitating treatments using LP-184 through genomics-guided therapy. LP-184 is a drug candidate in preclinical development, which has shown early indications of efficacy in solid tumors, as well as in glioblastoma and CNS cancers with specific genetic and biomarker profiles.

RADR is Lantern Pharma’s proprietary A.I. and machine learning platform, which leverages over 275 million data points across more than 140 drug-tumor interactions to predict the potential response patients will have to Lantern Pharma’s cancer drug candidates and to other drugs that it is reviewing and analyzing. Lantern Pharma continues expanding RADR with additional real-world data points, tumor-specific data sets, proprietary experimental data and validated drug-tumor models. The company is actively developing additional collaborations and partnerships that will help expand RADR both in terms of datasets and functionality.

The AACR (Free AACR Whitepaper) Annual Meeting highlights the work and discoveries of the world’s leading cancer experts and researchers. In response to the COVID-19 pandemic, this year’s meeting will be held virtually and features speakers from leading healthcare institutions, cancer research centers, large pharmaceutical companies and hospitals.

"We know that collaboration and the exchange of ideas among the world’s most renowned oncology experts is key to combatting cancer and improving patient outcomes," said Panna Sharma, CEO of Lantern Pharma. "Each year, the AACR (Free AACR Whitepaper) annual meeting convenes leading voices in cancer treatment from across the globe and is instrumental in advancing cancer research and individual therapies like those Lantern seeks to develop. We very much look forward to presenting our knowledge and methodologies being used to advance LP-184, and to applying the knowledge gained from the conference toward advancing and ultimately commercializing our own pipeline of cancer drugs, realizing long-term value for our shareholders."

POSTER PRESENTATION DETAILS:

Poster One:

"LP-184, a molecule with nanomolar potency, exhibits strong activity in lung cancers with KEAP1 and KRAS mutations," presented by Aditya Kulkarni, Ph.D.
Poster Session Title: Novel Antitumor Agents 1
Abstract # 1464
Poster Number: 4185

Poster Two:

"Machine learning-derived gene signature predicts strong sensitivity of several solid tumors to the alkylating agent LP-184," presented by Umesh Kathad, M.S.
Poster Session Title: Machine Learning
Abstract # 3305
Poster Number: 2090

Full abstracts for the poster presentations can be found at the AACR (Free AACR Whitepaper) annual meeting website, www.aacr.org. They will also be available after the presentations at the Company’s website – www.lanternpharma.com.

Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

On June 17, 2020 Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, reported the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock (Press release, Vical, JUN 17, 2020, View Source [SID1234561204]). Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $1.15, for total gross proceeds of approximately $20.1 million, before underwriting discounts and commissions and offering expenses payable by Brickell. The offering is expected to close on or about June 22, 2020, subject to the satisfaction or waiver of customary closing conditions.

Brickell anticipates using the net proceeds from the offering for research and development, including clinical trials, working capital and general corporate purposes.
Oppenheimer & Co. Inc. is acting as the sole book-running manager in connection with the offering and Lake Street Capital Markets, LLC is acting as lead manager.
The securities will be offered pursuant to a registration statement on Form S-1 (File No. 333-238298), which was declared effective by the Securities and Exchange Commission (the "SEC") on June 17, 2020, and an additional registration statement filed with the SEC on June 17, 2020 pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The offering is being made solely by means of a prospectus. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus and, when available, copies of the final prospectus relating to this offering can be obtained at the SEC’s website at www.sec.gov or from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at [email protected].
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference

On June 17, 2020 MannKind Corporation (NASDAQ:MNKD) reported that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT) (Press release, Mannkind, JUN 17, 2020, View Source [SID1234561203]). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.

A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at [email protected] or visit www.lythampartners.com/virtual.

Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

On June 17, 2020 Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, reported that it will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference (Press release, Mallinckrodt, JUN 17, 2020, View Source [SID1234561201]). Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.

Rigel to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

On June 17, 2020 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Dean Schorno, the company’s chief financial officer, reported that to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time (Press release, Rigel, JUN 17, 2020, View Source [SID1234561200]).

To access the live and subsequently archived webcast, go to the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.